Eversept Partners LP Sells 134,125 Shares of HealthEquity, Inc. $HQY

Eversept Partners LP trimmed its position in shares of HealthEquity, Inc. (NASDAQ:HQY) by 72.2% during the first quarter, HoldingsChannel.com reports. The firm owned 51,614 shares of the company’s stock after selling 134,125 shares during the period. Eversept Partners LP’s holdings in HealthEquity were worth $4,313,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Capricorn Fund Managers Ltd acquired a new position in HealthEquity in the 4th quarter valued at approximately $6,926,000. Oxbow Advisors LLC bought a new position in shares of HealthEquity during the first quarter valued at $3,147,000. Westfield Capital Management Co. LP lifted its holdings in shares of HealthEquity by 13.7% during the fourth quarter. Westfield Capital Management Co. LP now owns 1,952,452 shares of the company’s stock worth $178,864,000 after purchasing an additional 235,794 shares during the period. Wasatch Advisors LP lifted its holdings in shares of HealthEquity by 9.3% during the first quarter. Wasatch Advisors LP now owns 7,202,934 shares of the company’s stock worth $601,949,000 after purchasing an additional 613,288 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd bought a new stake in shares of HealthEquity in the fourth quarter worth $4,381,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Stock Performance

NASDAQ:HQY opened at $99.05 on Tuesday. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46. HealthEquity, Inc. has a twelve month low of $72.76 and a twelve month high of $105.96. The company has a fifty day moving average of $90.53 and a 200-day moving average of $84.90. The firm has a market capitalization of $8.28 billion, a P/E ratio of 37.10, a P/E/G ratio of 1.59 and a beta of 0.21.

HealthEquity (NASDAQ:HQY) last issued its earnings results on Thursday, May 28th. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.13. The business had revenue of $354.64 million for the quarter, compared to analyst estimates of $352.02 million. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. As a group, sell-side analysts anticipate that HealthEquity, Inc. will post 3.92 EPS for the current year.

Insider Activity

In related news, EVP Delano Ladd sold 7,500 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $675,000.00. Following the completion of the sale, the executive vice president directly owned 91,141 shares of the company’s stock, valued at $8,202,690. The trade was a 7.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gayle Furgurson Wellborn sold 2,439 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $219,510.00. Following the transaction, the director directly owned 19,733 shares in the company, valued at approximately $1,775,970. This trade represents a 11.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 17,905 shares of company stock worth $1,651,280. Company insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Weiss Ratings upgraded HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, June 5th. BMO Capital Markets raised HealthEquity from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $85.00 to $105.00 in a report on Thursday, April 9th. Royal Bank Of Canada upped their price target on HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a research report on Wednesday, June 3rd. Wells Fargo & Company set a $111.00 price target on HealthEquity in a research note on Monday, June 1st. Finally, Citizens Jmp increased their price target on HealthEquity from $110.00 to $111.00 and gave the company a “market outperform” rating in a research note on Monday, June 1st. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, HealthEquity currently has a consensus rating of “Moderate Buy” and an average target price of $110.93.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.